A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Sapanisertib (Primary) ; TAK 580 (Primary) ; Alisertib; Cetuximab; Irinotecan; Paclitaxel
- Indications Cancer
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 18 Apr 2017 Planned End Date changed from 1 Jul 2018 to 23 Dec 2017.
- 18 Apr 2017 Planned primary completion date changed from 1 Mar 2018 to 23 Dec 2017.
- 14 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Jul 2018.